Влияние программы дополнительного лекарственного обеспечения на доступность инновационных лекарственных средств и структуру российского фармацевтического рынка
The author studies relationships between medical representatives and physicians from the structural embeddedness perspective. Based on the research she discloses the existing practices of relationships between pharmaceutical companies and physicians, describes possible ways of resolving administrative and legal problems associated with new regulations of drug turnover. The author also gives attention to the dissolution of ties as an important element of network analysis.
An analysis of the influence of the world economic and financial crisis on the development of the global pharmaceutical market is given as well as an estimation of the economic situation in the pharmaceutical field, forecasts of the scenarios of its development in the crisis and post-crisis period, and the measures for overcoming the consequences of the world economic crisis.
In the context of global efforts to move towards universal coverage in health systems, this report reviews health financing reforms in the Republic of Moldova and looks in particular at how the population´s access to health services has been affected. In 2004, as has been widely documented elsewhere, wholesale reforms were made to the way in which government funds were used to fund health services, shifting the system overnight from a highly fragmented and inflexible one, to one in which funds for the health sector were pooled nationally, allowing improved risk-sharing as a result of greater flexibility to allocate funds in line with health needs. A new source of funding in the form of a payroll tax for health was also introduced directly leading to a growth in total levels of government health spending. A second phase of reforms starting in 2009 addressed the issue of gaps in population coverage under mandatory health insurance, with legislative measures taken to ensure that all citizens of Moldova had access to primary health care, and to ensure that the poor receive subsidized health insurance. Fiscal constraints have limited the full implementation of these reforms however. Moldova has shown that it is prepared to tackle difficult policy issues head on and has articulated clear goals for the sector. In particular, the Roadmap “Accelerating Reforms: addressing the needs of the health area through investment policies” approved on 1 March 2012, lays a clear agenda for the next phase or priority reforms focusing on principally on service delivery reorganization but also on health financing. This is the correct focus given that progress on a number of priority indicators such as equity in access to services and financial protection has been limited in recent years. This report summarizes the main impact of health financing reforms to date and agrees with the Roadmap about the major challenges for the coming decade, in particular the need to address inefficiencies in service delivery, but also to ensure that the close link between guaranteed benefits and available funding is maintained in future policy decisions.
Nowadays Russian drug market structure is inefficient in terms of high level of branded generic drugs. This requires improvement of policy measures in order to increase the affordability of innovative drugs, both domestic and imported. The paper describes special features of Russian pharmaceutical market and investigates how drug policy instruments affect the commercial market structure, focusing mainly on incentives to launch and sell innovative drugs.